{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:46:12Z","timestamp":1791981972756,"version":"4.4.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy (BCMA CAR-T) is an effective treatment of relapsed refractory multiple myeloma (MM). However, the pattern of infectious complications is not well elucidated. We performed a single-center retrospective analysis of infection outcomes up to 1 year after BCMA CAR-T for MM from 2018 to 2020. Fifty-five patients with MM were treated with BCMA CAR-T. Before lymphodepletion (LD), 35% of patients had severe hypogammaglobulinemia and 18% had severe lymphopenia. Most patients (68%) received bridging chemotherapy (BC) before LD. In the first month after CAR-T, 98% patients had grade 3 to 4 neutropenia. At 1 year after infusion, 76% patients had hypogammaglobulinemia. With a median follow-up of 6.0 months (95% confidence interval, 4.7-7.4), there were a total of 47 infection events in 29 (53%) patients: 40% bacterial, 53% viral, and 6% fungal. Most (92%) were mild-moderate and of the lower\/upper respiratory tract system (68%). Half of the infections (53%) occurred in the first 100 days after CAR-T infusion. Although no statistically significant risk factors for infection were identified, prior lines of therapy, use of BC, recent infections, and post\u2013CAR-T lymphopenia were identified as possible risk factors that need to be further explored. This is the largest study to date to assess infectious complications after BCMA CAR-T. Despite multiple risk factors for severe immunosuppression in this cohort, relatively few life-threatening or severe infections occurred. Further larger studies are needed to better characterize the risk factors for and occurrence of infections after BCMA CAR-T.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2020004079","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T16:15:25Z","timestamp":1632154525000},"page":"2045-2054","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":126,"title":["Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy"],"prefix":"10.1182","volume":"6","author":[{"given":"Swetha Kambhampati","family":"Thiruvengadam","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine"},{"name":"2University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sheng","sequence":"additional","affiliation":[{"name":"3Department of Epidemiology and Biostatistics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2313-3562","authenticated-orcid":false,"given":"Chiung-Yu","family":"Huang","sequence":"additional","affiliation":[{"name":"3Department of Epidemiology and Biostatistics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8451-955X","authenticated-orcid":false,"given":"Sophia","family":"Bylsma","sequence":"additional","affiliation":[{"name":"2University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Lo","sequence":"additional","affiliation":[{"name":"4Department of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Kennedy","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine"},{"name":"2University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-7028","authenticated-orcid":false,"given":"Kelsey","family":"Natsuhara","sequence":"additional","affiliation":[{"name":"5Department of Medicine, UCSF Medical Center, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine"},{"name":"2University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Wolf","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine"},{"name":"2University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Shah","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine"},{"name":"2University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy W.","family":"Wong","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine"},{"name":"2University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"issue":"8","key":"2025042209413610100_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med."},{"issue":"39","key":"2025042209413610100_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"4","key":"2025042209413610100_bib3","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma."},{"issue":"15","key":"2025042209413610100_bib4","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"2025042209413610100_bib5","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: current management and future directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"HemaSphere."},{"issue":"26","key":"2025042209413610100_bib6","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood."},{"issue":"1","key":"2025042209413610100_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood."},{"issue":"8","key":"2025042209413610100_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J."},{"issue":"1","key":"2025042209413610100_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv."},{"key":"2025042209413610100_bib10","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1182\/blood-2019-131170","article-title":"Infectious complications associated with CAR T-cell therapy","volume":"134","author":"Mikkilineni","year":"2019","journal-title":"Blood."},{"issue":"3","key":"2025042209413610100_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1081-1206(10)60665-5","article-title":"Assessment and clinical interpretation of reduced IgG values","volume":"99","author":"Agarwal","year":"2007","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"4","key":"2025042209413610100_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"12","key":"2025042209413610100_bib13","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.bbmt.2007.08.049","article-title":"Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease","volume":"13","author":"van Burik","year":"2007","journal-title":"Biol Blood Marrow Transplant."},{"issue":"2","key":"2025042209413610100_bib14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbmt.2015.09.013","article-title":"Infections after transplantation of bone marrow or peripheral blood stem cells from unrelated donors","volume":"22","author":"Young","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"issue":"8","key":"2025042209413610100_bib15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/sim.4780100806","article-title":"Statistical analysis of repeated events forming renewal processes","volume":"10","author":"Aalen","year":"1991","journal-title":"Stat Med."},{"issue":"4","key":"2025042209413610100_bib16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J R Stat Soc Series B Stat Methodol."},{"key":"2025042209413610100_bib17","first-page":"4","article-title":"Infectious complications of BCMA-targeted and CD19-targeted chimeric antigen receptor T-cell immunotherapy","volume":"136","author":"Thiruvengadam","year":"2020","journal-title":"Blood."},{"issue":"1","key":"2025042209413610100_bib18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"18","key":"2025042209413610100_bib19","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med."},{"issue":"4","key":"2025042209413610100_bib20","doi-asserted-by":"crossref","first-page":"e13114","DOI":"10.1111\/tid.13114","article-title":"Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma","volume":"21","author":"Rahman","year":"2019","journal-title":"Transpl Infect Dis."},{"issue":"1","key":"2025042209413610100_bib21","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.3324\/haematol.2014.114025","article-title":"Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies","volume":"100","author":"Teh","year":"2015","journal-title":"Haematologica."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/7\/2045\/2370563\/blooda_adv-2020-004079-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/7\/2045\/2370563\/blooda_adv-2020-004079-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T13:41:45Z","timestamp":1745329305000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/7\/2045\/476960\/Infectious-complications-in-patients-with-relapsed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,4,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020004079","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,20]]}}}